Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Sartor on Promising Treatment Approaches in Prostate Cancer

January 25th 2020

A. Oliver Sartor, MD, discusses research on immunotherapy, radiopharmaceuticals, and combinations in prostate cancer.

Dr. Penson on Questions Regarding Next-Generation AR Inhibitors in Prostate Cancer

January 25th 2020

David F. Penson, MD, MPH, MMHC, discusses questions regarding next-generation androgen receptor (AR) inhibitors in prostate cancer.

Dr. Kohli on Drugs That Have Been Evaluated in mCRPC

January 25th 2020

Manish Kohli, MD, discusses drugs that have been evaluated in metastatic castration-resistant prostate cancer.

Dr. Hwang on Treatment Selection in Metastatic Castration-Sensitive Prostate Cancer

January 24th 2020

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses treatment selection in newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC).

Dr. Paulson on Molecular Testing in Oncology

January 24th 2020

R. Steven Paulson, MD, discusses molecular testing in oncology.

Dr. Heath on Remaining Challenges in Nonmetastatic CRPC

January 23rd 2020

Elisabeth I. Heath, MD, FACP, discusses a remaining challenge in nonmetastatic castration-resistant prostate cancer.

Dr. Koo on Metastasis-Directed Therapy in Prostate Cancer

January 21st 2020

Phillip J. Koo, MD, division chief of Diagnostic Imaging, Banner MD Anderson Cancer Center, discusses the use of metastasis-directed therapy in prostate cancer.

FDA Grants Priority Review to Olaparib for HRR-Mutant mCRPC

January 21st 2020

The FDA has granted a priority review designation to a supplemental new drug application for olaparib (Lynparza) for the treatment of patients with metastatic castration-resistant prostate cancer who have deleterious or suspected deleterious or somatic homologous recombination repair gene mutations, and who have also progressed on prior therapy with a new hormonal agent.

Dr. Mohler on Need for Genetic Counselors for Early Detection of Prostate Cancer

January 20th 2020

James L. Mohler, MD, discusses the need for genetic counselors in the detection and treatment of prostate cancer.

FDA Approvals Boost Competition in Treatment Landscapes

January 18th 2020

Therapeutic developments in cancer were rewarded with a wave of approvals in 2019.

Dr. Bryce on Next-Generation Radiopharmaceuticals in Prostate Cancer

January 17th 2020

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the use of next-generation radiopharmaceuticals in prostate cancer.

FDA Grants Priority Review to Rucaparib for mCRPC

January 16th 2020

The FDA has granted a priority review designation to a supplemental new drug application for rucaparib for the treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castration-resistant prostate cancer.

Dr. Aoun on Imaging Modalities in Prostate Cancer

January 14th 2020

Hussein Aoun, MD, a radiologist at Barbara Ann Karmanos Cancer Institute, discusses the imaging modalities that are currently being used in prostate cancer and how they compare with conventional imaging modalities.

SITC Poised to Expand Toolkit of Immunotherapy Guidelines

January 11th 2020

The Society for Immunotherapy of Cancer is developing a growing menu of guidelines with treatment algorithms for specific cancer types to help practicing oncologists navigate the appropriate use of this emerging modality.

CARD Trial Establishes Cabazitaxel as a Third-Line Standard in mCRPC

January 9th 2020

Celestia S. Higano, MD, FACP, provides perspective on data from the CARD trial and their implications on clinical practice.

Dr. Chang on the Evolution of Surgical Techniques in Prostate Cancer

January 9th 2020

Sam S. Chang, MD, MBA, discusses the evolution of surgical techniques in prostate cancer.

Dr. Heath on Recent Approvals in Nonmetastic Prostate Cancer

January 9th 2020

Elisabeth I. Heath, MD, FACP, discusses apalutamide, enzalutamide, and darolutamide, which have all been approved for use in nonmetastatic castration-resistant prostate cancer.

Dr. Hwang on Choosing Agents for Prostate Cancer Treatment

January 8th 2020

Clara Hwang, MD, discusses factors that can be used to decide what agent to use in the frontline setting for patients with metastatic castration-sensitive or castration-resistant prostate cancer.

Novel Imaging Slated to Change Trajectory of Prostate Cancer Treatment

January 7th 2020

Hussein Aoun, MD, discusses the use of novel imaging modalities and contrasted them with conventional imaging tools in prostate cancer.

Antiandrogens Augment Growing Armamentarium in Metastatic Prostate Cancer

January 3rd 2020

Clara Hwang, MD, discusses key trials that have shaped the current treatment paradigms of metastatic castration-sensitive prostate cancer and metastatic castration-resistant prostate cancer.